基本描述

别名	盐酸左氧氟沙星盐酸盐 \| 1-金刚烷乙胺盐酸盐 \| α-甲基-1-金刚烷甲胺盐酸盐 \| 盐酸金刚乙胺
英文别名	1-(1-Adamantyl)ethylamine hydrochloride, 99% \| 1-(ADAMANTAN-1-YL)ETHAN-1-AMINE HYDROCHLORIDE \| MLS002548886 \| RIMANTADINE HYDROCHLORIDE (MART.) \| Rimantadine hydrochloride [USAN:USP] \| Rimantadine, HCl \| 1-(1-Aminoethyl)adamantane HCl \| Algirem \| DTXCID30
规格或纯度	≥99%
英文名称	1-(1-Adamantyl)ethylamine hydrochloride
生化机理	M2质子通道抑制剂。在体内抑制甲型流感病毒。与盐酸金刚烷胺相比，具有更高的血脑屏障通透性。口服具有活性。
运输条件	常规运输
作用类型	抑制剂
备注	如果有可能，您尽量在使用的当天配置溶液，并在当天使用完它。但是，如果您需要预先配制储备溶液，我们建议您将溶液等份保存在-20°C的密封小瓶中。通常，它们最多可以使用一个月。在使用前和打开样品瓶之前，我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度，用法和处理的建议吗？请访问我们的常见问题（FAQ）页面以获取更多详细信息。
产品介绍	Product Application: 1-(1-Adamantyl)ethylamine hydrochloride is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older).
纯度	≥99%

名称和识别符

PubChem SID	488182078
IIUPAC Name	1-(1-adamantyl)ethanamine;hydrochloride
INCHI	1S/C12H21N.ClH/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12;/h8-11H,2-7,13H2,1H3;1H
InChi Key	OZBDFBJXRJWNAV-UHFFFAOYSA-N
Smiles	CC(C12CC3CC(C1)CC(C3)C2)N.Cl
Isomeric SMILES	CC(C12CC3CC(C1)CC(C3)C2)N.Cl
分子量	215.77
Reaxy-Rn	3623918
Reaxys-RN link address	https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=3623918&ln=

化学和物理性质

溶解性	Freely soluble in water.
熔点	375°C
分子量	215.760 g/mol
XLogP3
氢键供体数Hydrogen Bond Donor Count	2
氢键受体数Hydrogen Bond Acceptor Count	1
可旋转键计数Rotatable Bond Count	1
精确质量Exact Mass	215.144 Da
单同位素质量Monoisotopic Mass	215.144 Da
拓扑极表面积Topological Polar Surface Area	26.000 Å²
重原子数Heavy Atom Count	14
形式电荷Formal Charge	0
复杂度Complexity	180.000
同位素原子数Isotope Atom Count	0
定义的原子立体中心计数Defined Atom Stereocenter Count	0
未定义的原子立体中心计数Undefined Atom Stereocenter Count	1
定义的键立体中心计数Defined Bond Stereocenter Count	0
未定义的键立体中心计数Undefined Bond Stereocenter Count	0
所有立体化学键的总数The total count of all stereochemical bonds	0
共价键合单元计数Covalently-Bonded Unit Count	2

安全和危险性（GHS）

象形图	GHS07
信号词	警告
危险声明	H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激
预防措施声明	P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P264: 处理后要彻底洗手。 P270: 使用本产品时，请勿进食、饮水或吸烟。 P271: 仅在室外或通风良好的地方使用。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P321: 特殊处理（请参阅此标签上的...）。 P330: 漱口 P302+P352: 如皮肤沾染：用水充分清洗。 P304+P340: 如误吸入：将人转移到空气新鲜处，保持呼吸舒适体位。 P305+P351+P338: 如进入眼睛：用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出，取出隐形眼镜。继续冲洗。 P362+P364: 脱掉沾污的衣服，清洗后方可重新使用。 P405: 密闭存放 P403+P233: 存放在通风良好的地方。保持容器密闭。 P501: 将内容物/容器处理到。。。 P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。 P301+P317: 如果被吞咽：请寻求医疗帮助。 P337+P317: 如果眼睛刺激持续：寻求医疗帮助。 P332+P317: 如果出现皮肤刺激：请寻求医疗帮助。 P319: 如果你感到不适，请寻求医疗帮助。
WGK Germany	3
RTECS	AU4717000
Merck Index	8224
个人防护装备	dust mask type N95 (US)， Eyeshields， Gloves

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到13个结果

批号(Lot Number)	证书类型	货号
L1721050	分析证书	A118559
G2113060	分析证书	A118559
E1921074	分析证书	A118559
B2304074	分析证书	A118559
B2304092	分析证书	A118559
B2304093	分析证书	A118559
B2304094	分析证书	A118559
B2304095	分析证书	A118559
B2304097	分析证书	A118559
B2304098	分析证书	A118559
B2304099	分析证书	A118559
B2304116	分析证书	A118559
E2312091	分析证书	A118559

显示更多⌵

引用文献

1. Segovia M et al.. (2019) Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation.. Cancer Cell, 35 (5): (767-781.e6). [PMID:31085177]
2. G G U Rohde. (2011-08-03) [Influenza : clinical symptoms, diagnostics and therapy].. Der Internist, 52 ((9)): (1047-1052). [PMID:21809066]
3. Belen Puente,Esther Hernandez,Susana Perez,Luis Pablo,Esther Prieto,Maria Angeles Garcia,Miguel Angel Bregante. (2011-11-15) Determination of memantine in plasma and vitreous humour by HPLC with precolumn derivatization and fluorescence detection.. Journal of chromatographic science, 49 ((10)): (745-752). [PMID:22080801]
4. Linh Tran,Sy Bing Choi,Belal O Al-Najjar,Muhammad Yusuf,Habibah A Wahab,Ly Le. (2011-12-14) Discovery of potential M2 channel inhibitors based on the amantadine scaffold via virtual screening and pharmacophore modeling.. Molecules (Basel, Switzerland), 16 ((12)): (10227-10255). [PMID:22158591]
5. Sander A A Kooijmans,Danielle Senyschyn,Muguntha M Mezhiselvam,Julia Morizzi,Susan A Charman,Babette Weksler,Ignacio-Andres Romero,Pierre-Olivier Couraud,Joseph A Nicolazzo. (2012-02-23) The involvement of a Na⁺- and Cl⁻-dependent transporter in the brain uptake of amantadine and rimantadine.. Molecular pharmaceutics, 9 ((4)): (883-893). [PMID:22352408]
6. Jonathan Hsu,Nancy Santesso,Reem Mustafa,Jan Brozek,Yao Long Chen,Jessica P Hopkins,Adrienne Cheung,Gayane Hovhannisyan,Liudmila Ivanova,Signe A Flottorp,Ingvil Saeterdal,Arthur D Wong,Jinhui Tian,Timothy M Uyeki,Elie A Akl,Pablo Alonso-Coello,Fiona Smaill,Holger J Schünemann. (2012-03-01) Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies.. Annals of internal medicine, 156 ((7)): (512-524). [PMID:22371849]
7. Tijana Ivanovic,Rutger Rozendaal,Daniel L Floyd,Milos Popovic,Antoine M van Oijen,Stephen C Harrison. (2012-03-14) Kinetics of proton transport into influenza virions by the viral M2 channel.. PloS one, 7 ((3)): (e31566-e31566). [PMID:22412838]
8. Loren B Andreas,Matthew T Eddy,James J Chou,Robert G Griffin. (2012-04-07) Magic-angle-spinning NMR of the drug resistant S31N M2 proton transporter from influenza A.. Journal of the American Chemical Society, 134 ((17)): (7215-7218). [PMID:22480220]
9. Lora Simeonova,Galina Gegova,Angel S Galabov. (2012-05-24) Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice.. Antiviral research, 95 ((2)): (172-181). [PMID:22617756]
10. V A Shibnev,T M Garaev,M P Finogenova,E S Shevchenko,E I Burtseva. (2012-07-21) New adamantane derivatives can overcome resistance of influenza A(H1N1)pdm2009 and A(H3N2) viruses to remantadine.. Bulletin of experimental biology and medicine, 153 ((2)): (233-235). [PMID:22816091]
11. Yuxin Zhang,Hujun Shen,Mingbo Zhang,Guohui Li. (2013-01-05) Exploring the proton conductance and drug resistance of BM2 channel through molecular dynamics simulations and free energy calculations at different pH conditions.. The journal of physical chemistry. B, 117 ((4)): (982-988). [PMID:23286443]
12. Bo OuYang,Shiqi Xie,Marcelo J Berardi,Xinhao Zhao,Jyoti Dev,Wenjing Yu,Bing Sun,James J Chou. (2013-06-07) Unusual architecture of the p7 channel from hepatitis C virus.. Nature, 498 ((7455)): (521-525). [PMID:23739335]
13. George Atiee,Kenneth Lasseter,Sharon Baughman,Amy McCullough,Phil Collis,Alan Hollister,Jaime Hernandez. (2011-10-01) Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans.. Journal of clinical pharmacology, 52 ((9)): (1410-1419). [PMID:21960669]
14. Saumil Doshi,Laurie Kamimoto,Lyn Finelli,Alejandro Perez,Arthur Reingold,Ken Gershman,Kimberly Yousey-Hindes,Kathryn Arnold,Patricia Ryan,Ruth Lynfield,Craig Morin,Joan Baumbach,Emily B Hancock,Nancy M Bennett,Shelley Zansky,Ann Thomas,William Schaffner,Alicia M Fry. (2011-10-21) Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009.. The Journal of infectious diseases, 204 ((12)): (1848-1856). [PMID:22013219]
15. Georgina Cirrincione-Dall,Barbara J Brennan,Rosa M Ballester-Sanchis,Mercidita T Navarro,Brian E Davies. (2011-11-01) Pharmacokinetics and safety of coadministered oseltamivir and rimantadine in healthy volunteers: an open-label, multiple-dose, randomized, crossover study.. Journal of clinical pharmacology, 52 ((8)): (1255-1264). [PMID:22039289]
16. Rafal M Pielak,Kirill Oxenoid,James J Chou. (2011-11-15) Structural investigation of rimantadine inhibition of the AM2-BM2 chimera channel of influenza viruses.. Structure (London, England : 1993), 19 ((11)): (1655-1663). [PMID:22078564]
17. Mona Alqazzaz,Andrew J Thompson,Kerry L Price,Hans-Georg Breitinger,Sarah C R Lummis. (2012-01-03) Cys-loop receptor channel blockers also block GLIC.. Biophysical journal, 101 ((12)): (2912-2918). [PMID:22208189]
18. Suelen F Sucena,Raphael E F Paiva,Camilla Abbehausen,Ives B Mattos,Marcelo Lancellotti,André L B Formiga,Pedro P Corbi. (2012-01-20) Chemical, spectroscopic characterization, DFT studies and antibacterial activities in vitro of a new gold(I) complex with rimantadine.. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 89 (114-118). [PMID:22257715]
19. Márcia G Alves Galvão,Marilene Augusta Rocha Crispino Santos,Antonio Jl Alves da Cunha. (2012-01-20) Amantadine and rimantadine for influenza A in children and the elderly.. The Cochrane database of systematic reviews, 1 (CD002745-CD002745). [PMID:22258950]
20. Guang-Quan Wang,Yan-Fang Qin,Li-Ming Du,Jun-Fei Li,Xu Jing,Yin-Xia Chang,Hao Wu. (2012-09-11) Determination of amantadine and rimantadine using a sensitive fluorescent probe.. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 98 (275-281). [PMID:22959366]
21. Loren B Andreas,Alexander B Barnes,Björn Corzilius,James J Chou,Eric A Miller,Marc Caporini,Melanie Rosay,Robert G Griffin. (2013-03-14) Dynamic nuclear polarization study of inhibitor binding to the M2(18-60) proton transporter from influenza A.. Biochemistry, 52 ((16)): (2774-2782). [PMID:23480101]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

=

浓度

x

体积

x

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

x

体积 1 (V1)

=

浓度 2 (C2)

x

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

=

质量（小瓶）

÷

所需的复溶浓度

货号 (SKU)	包装规格	是否现货
A118559-1g	1g	现货
A118559-5g	5g	现货
A118559-25g	25g	现货
A118559-100g	100g	现货
A118559-500g	500g	现货

1-(1-金刚烷基)乙基胺盐酸盐

库存信息

库存信息

库存信息

库存信息

库存信息

基本描述

名称和识别符

化学和物理性质

安全和危险性（GHS）

质检证书（CoA,COO,BSE/TSE 和分析图谱)

显示更多⌵

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器